脯氨酸羟化酶2在糖尿病视网膜病变中的研究进展

Progress of Proline Hydroxylase 2 in Diabetic Retinopathy

糖尿病性视网膜病变,尤其是增殖性糖尿病性视网膜病变导致的玻璃体出血以及牵拉性视网膜脱离是导致糖尿病患者失明的主要原因之一。近些年来,国内外许多研究人员寻找DR的发病机制,并致力于并研究其相关的因子及通路,例如缺氧诱导因子1,血管内皮生长因子等分子。目前,大量的抗VEGF类药物用于临床治疗视网膜新生血管类疾病,然而临床观察发现,部分患者单纯使用抗VEGF类药物并不能彻底控制新生血管的生成。所以新的药物治疗亟待研究。脯氨酸羟化酶2是HIF-1α的降解酶,而HIF-1α可以调节VEGF、EPO等多种因子的表达,可能成为治疗DR的新的治疗突破点。本文就国内外对PHD2在糖尿病视网膜病变中的相关研究进展进行总结。

Diabetic retinopathy,especially the vitreous hemorrhage and traction retinal detachment which are caused by proliferative diabetic retinopathy,is one of the leading causes of blindness in diabetic patients.In re-cent years,many researchers at home and abroad have searched for the pathogenesis of DR.For example,hypoxia inducible factor-1,vascular endothelial growth factor and other molecules.Currently,a large number of anti-vegf drugs are used in clinical treatment of retinal neovascularization.However,the clinical observation is that,in some cases,the use of antivegf drugs is not entirely possible to control the production of new blood vessels.So new medication needs to be studied.The proline hydroxylase domain 2(PHD2)is the degradation enzyme of HIF-la.HIF-la can regulate the expression of various factors such as VEGF and EPO.It could be a new break-through in the treatment of DR.This paper summarized the progress of PHD2 in diabetic retinopathy.